Published in Onco Targets Ther on September 07, 2010
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol (2012) 0.91
Signal transduction molecule patterns indicating potential glioblastoma therapy approaches. Onco Targets Ther (2013) 0.76
Primitive Neuroectodermal Tumor with Glioblastoma Multiforme Components in an Adult: A Collision Tumor. Cureus (2016) 0.75
Enhancement of temozolomide stability by loading in chitosan-carboxylated polylactide-based nanoparticles. J Nanopart Res (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol (2006) 11.56
Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci (2007) 11.11
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
Angiogenesis in brain tumours. Nat Rev Neurosci (2007) 6.82
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med (1980) 4.90
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol (2006) 4.88
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol (2003) 4.17
Glioma extent of resection and its impact on patient outcome. Neurosurgery (2008) 4.02
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol (1999) 3.30
Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res (1992) 3.15
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev (1997) 2.62
Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 2.42
Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol (2002) 2.40
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol (1998) 2.39
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 2.39
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest (1991) 2.32
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer (2009) 2.23
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer (1993) 2.18
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol (2007) 2.11
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol (2006) 2.11
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys (2008) 2.08
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res (2008) 1.94
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res (2004) 1.92
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg (2009) 1.91
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer (2006) 1.84
PCV chemotherapy for recurrent glioblastoma multiforme. Neurology (2001) 1.80
Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer (1995) 1.69
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer (1999) 1.66
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res (2006) 1.64
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol (2009) 1.58
Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol (2007) 1.36
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology (2004) 1.36
Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer (2009) 1.35
Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys (2000) 1.34
In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs (1997) 1.32
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol (2009) 1.30
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology (2007) 1.20
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res (2007) 1.19
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep (2006) 1.15
Salvage therapy in patients with glioblastoma: is there any benefit? Cancer (2003) 1.11
Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol (2008) 1.07
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol (2004) 0.99
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol (2004) 0.96
Salvage temozolomide for prior temozolomide responders. Cancer (2005) 0.95
Is reoperation for recurrence of glioblastoma justified? Oncol Rep (2000) 0.93
Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol (1999) 0.92
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol (2008) 0.92
Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol (2004) 0.89
ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol (2008) 0.88
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology (2004) 0.87
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol (2008) 0.86
Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med (2001) 0.83
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. Neurosurg Focus (2006) 0.82
Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol (2008) 0.82
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol (2006) 0.82
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci (2009) 0.80
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro Oncol (2004) 0.79
Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic? Clin Cancer Res (2000) 0.79
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer (2003) 0.78
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer (2003) 0.78